###### Strengths and limitations of this study

-   Obtaining representative stakeholder feedback is an essential step in ensuring that a risk prediction tool is feasible and acceptable for use in clinical practice.

-   This tool could be adapted to newer breast cancer treatments and for other cancers.

-   Non-probability sampling may increase the risk of selection bias.

-   Recruitment is limited to patients with breast cancer where fertility was discussed prior to cancer treatment, findings may not be applicable where fertility was not discussed.

-   This study is being conducted in the Australian setting, findings may not be generalisable to different health settings.

Introduction {#s1}
============

Globally, breast cancer is the most frequent cancer diagnosis in reproductive-aged women, with approximately 100 000 women younger than 40 years diagnosed annually worldwide, representing one-quarter of new breast cancer cases.[@R1] In Australia, most women are diagnosed with early-stage disease, and with current treatment, the 5-year survival rate for women diagnosed with breast cancer is often excellent (90.8%).[@R4] Recommended treatment can include gonadotoxic chemotherapeutic agents and thus poses a potential threat to fertility by destroying the eggs stored in the ovaries.[@R5] If the number of eggs is substantially depleted, early menopause and/or permanent infertility can result,[@R7] and will commonly present as amenorrhoea (ie, cessation of the menstrual cycle).[@R8] Infertility and/or early menopause is a recognised long-term adverse effect of breast cancer treatment in premenopausal women and has serious implications for the survivorship experience of these women.[@R8]

Fertility is well established to be a priority for many young premenopausal patients with breast cancer. More than half are concerned about their future fertility, and 50%--76% wish to consider pregnancy following cancer treatment.[@R10] This number is likely to increase with the social trends of delayed motherhood until older reproductive ages.[@R13] Concerns about the potential risk of infertility and the inability to conceive in the future have direct implications for treatment efficacy and long-term physical and emotional health[@R10]---specifically it may influence patients to choose less optimal adjuvant therapies to reduce impact on fertility[@R10] or the uptake of fertility preservation options despite potential physical, emotional and financial burden.[@R22] Young women with breast cancer actively seek and desire knowledge, and improved information translates into better health outcomes.[@R25] Core to making informed fertility-related decisions is an understanding of the risk of infertility, but the currently available information about fertility outcomes following breast cancer treatment can only determine broad risk categories (eg, intermediate risk: 30%--70% risk of infertility)[@R27] and individual factors which are known to affect fertility in women (eg, age, body mass index, smoking, previous fertility, serum ovarian markers) are not included in the risk prediction. There is a gap in personalised information to inform young patients with breast cancer about likely fertility outcomes after treatment.[@R28] To meet their unmet information needs, young patients frequently use the internet to seek more accessible and consolidated information about post-treatment reproductive consequences.[@R31] Therefore, an evidence-based and individualised online risk prediction tool may provide reliable and easy-to-access information to address the gap and better manage the fertility-related needs.[@R32]

Accurate prediction of infertility after breast cancer treatment is complex and requires consideration of baseline fertility and the likely impact of planned cancer treatments on fertility.[@R28] There is growing evidence that baseline fertility indicators prior to breast cancer treatment may predict the likelihood of developing amenorrhoea after treatment.[@R29] However, no previous studies have included baseline demographic and lifestyle factors, as well as serum ovarian markers and cancer treatment factors, all together, to predict fertility. To address this gap, we are developing the fertility after cancer predictor (FoRECAsT) tool for young patients with breast cancer which considers both baseline fertility indicators and the impact of planned cancer treatment on fertility. Based on the input information, it will provide an individualised risk of amenorrhoea at different time points after initial treatment (12 months, 24 months, 36 months, 48 and 60 months) to assess longitudinal changes in infertility risk, with amenorrhoea being a surrogate marker for infertility. The tool will allow users to input individual data (baseline demographic and lifestyle factors, serum ovarian markers and recommended breast cancer treatment) to determine a personalised risk of infertility after breast cancer treatment.

There are two key parts to the FoRECAsT tool---the algorithm development and the user interface. To develop the risk prediction algorithm (part one), authors from studies exploring variables related to fertility at baseline and impact of breast cancer treatment ([table 1](#T1){ref-type="table"})[@R29] have been invited to join the FoRECAsT Collaboration and contribute their data to the FoRECAsT database and these data are being used to build a predictive model.

###### 

Candidate predictors for fertility

  ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lifestyle factors                   Age, race, body mass index, diet, exercise, smoking, alcohol, caffeine, drugs.
  Medical history                     Prior (in)fertility and IVF, menstruation history, tubal and gynaecological disease, endometriosis, polycystic ovary syndrome, sexually transmitted infections, pelvic surgery, family history of (in)fertility and menopause.
  Serum markers of ovarian function   Follicle stimulating hormone, luteinising hormone, estradiol, inhibin B, antimullerian hormone, antral follicle count, ovarian volume.
  Cancer factors                      Age at diagnosis, stage, receptor status, type of treatment (dose and duration).
  ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IVF, in vitro fertilization.

The algorithm will use Bayesian inference technique, which is the preferred method in complex algorithm development, in combination with Markov chain Monte Carlo simulations.[@R45] From the algorithm, a working prototype of the tool will be developed (part two) as a proof of concept. To achieve part 2 and ensure that the tool is widely used clinically to facilitate oncofertility decision making, the user interface will be developed in consultation with stakeholders including patients and patient advocacy groups. This protocol reports on a key aspect of this consultation process. Findings from this part of the study will be used to design the user interface of the FoRECAsT (prototype) tool ensuring it is easy to use and understand. There are successive steps to validate the predictive algorithm and evaluate the tool prior to implementation in clinical practice.

Objectives {#s1-1}
----------

The main purpose of this study is to explore perceptions, ideas and opinions from young patients with breast cancer and clinicians regarding the design and feasibility of implementing the FoRECAsT tool including barriers and facilitators. Findings will also inform breast cancer patients' and clinicians' preferences of where and when the FoRECAsT tool might be used.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

A cross-sectional exploratory study is being conducted through semistructured in-depth telephone interviews with key stakeholders.

Study participants/stakeholders {#s2-2}
-------------------------------

The following stakeholders are included in our study:

a.  Patient group: 15--20 patients with breast cancer.

b.  Clinician group:

    -   15--20 breast surgeons.

    -   15--20 breast medical oncologists.

    -   15--20 breast care nurses.

    -   15--20 fertility specialists.

    -   15--20 fertility preservation nurses.

The sample size is an appropriate minimum sample required for meaningful outcomes. However, as per qualitative methodology, participants will continue to be recruited until informational redundancy is achieved.[@R50]

Eligibility criteria {#s2-3}
--------------------

### Patients with breast cancer {#s2-3-1}

#### Inclusion criteria {#s2-3-1-1}

To be eligible to participate patients with breast cancer must be (1) female, (2) diagnosed within the last 5 years.

\(3\) aged 18--40 years (4) premenopausal at breast cancer diagnosis (5) have evidence of prior discussion with a healthcare provider about the risk of developing infertility after breast cancer treatment either through referral to a fertility specialist or documented discussion inpatient notes (so as not to cause distress in those who had not had a prior discussion about potential infertility), (6) concerned about future fertility after chemotherapy and/or have not completed their family (as identified by the treatment team), (7) able to give informed written consent and (8) able to speak and understand English.

#### Exclusion criteria {#s2-3-1-2}

Women with metastatic breast cancer and women diagnosed with gestational breast cancer.

### Clinicians {#s2-3-2}

#### Inclusion criteria {#s2-3-2-1}

To be eligible to participate clinicians who: (1) have a valid Australian License for practice, (2) have at least 1 year of clinical experience in their respective discipline, (3) consult to women with breast cancer, (4) will be able to give informed written consent and (5) will able to speak and understand English.

Recruitment {#s2-4}
-----------

Recruitment started in September 2018 and is still ongoing. As per qualitative methodology, participants will continue to be recruited until informational redundancy is achieved. Patients with breast cancer are being recruited using purposive sampling by the breast care nurses from the joint Breast Service of Peter MacCallum Cancer Centre, Royal Melbourne Hospital and Royal Women's Hospital. [Figure 1](#F1){ref-type="fig"} illustrates the recruitment of patients with breast cancer. Clinicians are being recruited using an e-flyer through their respective online communities across Australia (except northern territory and Tasmania due to ethics committee coverage), that is, Breast Surgeons of Australia and New Zealand, Medical Oncology Group of Australia, Fertility Society of Australia, Cancer Nurses Society of Australia and McGrath Foundation. [Figure 2](#F2){ref-type="fig"} shows the recruitment of clinicians. Participation is voluntary, and participants may choose not to participate in the study or may withdraw from the study at any time. There will be an opportunity for participants to ask the research team any questions regarding the study. Invited participants, who do not respond, will be followed up with a second invitation 2 weeks after initial contact.

![Illustration of the recruitment of patients with breast cancer.](bmjopen-2019-033669f01){#F1}

![Illustration of the recruitment of clinicians.](bmjopen-2019-033669f02){#F2}

Data collection {#s2-5}
---------------

In-depth telephone interviews are guided by semistructured interview schedules and carried out by the research team. Consented participants are asked to review the draft FoRECAsT tool to provide their feedback. The interview schedules are structured in consultation with clinical experts and qualitative research specialists based on Aizen's theory of planned behaviour.[@R51] They are customised to the level of stakeholders to allow questioning strategy and conversations to be more flexible.

Each interview is anticipated to last for 15--20 min. Interviews are audio recorded on a portable, electronic digital voice recorder (Olympus VN-731PC) and transcribed verbatim. The audio recordings and transcripts have been securely stored in a password-protected folder on The University of Melbourne server with access permitted to authorised personnel only. Verbal informed consents are obtained for audio recording the interview. Interviews will be conducted until saturation is reached.[@R50] Patients and clinicians who consent to be interviewed have been offered the opportunity to view a copy of the transcripts prior to data analysis.

Patient and public involvement {#s2-6}
------------------------------

The study is supported by a consumer/patient who is a part of the working party and involved in the design of the study, and preparation of all the study materials from the patient's perspective. All interested participants will be sent a summary report of the results via email or mail with deidentified aggregated findings.

Outcome measures {#s2-7}
----------------

Sociodemographic data are collected from each participating patient with breast cancer and clinician. Patients with breast cancer are asked about their current age, the highest level of education attained, employment status, stage of cancer, relationship status and fertility history. Clinicians are asked about their age, years of clinical experience and proportion of patients seen with breast cancer.

Qualitative data are focusing on five topics ([table 2](#T2){ref-type="table"}):

###### 

Semistructured interviews topic guides for participants

  Broad topics                                                 Specific topics
  ------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Interest in using the infertility risk prediction tool   Extent of information received/delivered about risk of infertility, decision making with \*current infertility risk calculator', perceived satisfaction in using current calculators, interest in having a more accurate infertility risk prediction tool
  2\. Access and confidentiality                               Requirements around access and user interface, security, confidentiality of input information, technical skill.
  3\. User attributes                                          Perceptions of ease of use and preferences for data entry.
  4\. Impact on fertility consultation                         Perceptions of impact on fertility consultation.
  5\. Anticipated outcomes and benefits                        Benefits of using a more accurate tool, barriers and additional suggestions to better meet fertility-related needs.

\*Current infertility risk calculator' refers to the commonly used existing calculator for fertility risk prediction following breast cancer treatment.[@R27]

1.  Interest in using the tool.

2.  Access and confidentiality.

3.  User attributes.

4.  The potential impact of the tool on consultation.

5.  Anticipated outcomes and benefits.

Data analysis {#s2-8}
-------------

The processes of data collection and data analysis are ongoing. Transcripts are being imported into a qualitative data analysis software (QRS NVivo V.12---QRS International, Doncaster, Victoria, Australia) to facilitate data management and analyses. The five broad areas are developed based on the theoretical framework of planned behaviour.[@R51] Transcripts are coded line-by-line identifying keywords, concepts and reflections in accordance with the framework of Miles and Huberman,[@R52] a widely used framework for qualitative research methodology. Coding is being conducted using an iterative process: starting with coding for broad themes, before coding into hierarchical categories and subthemes.

To ensure the integrity and consistency of the codes and reduce bias, codes will be reviewed by the qualitative research specialist. The research team will discuss the coding tree and reach consensus. Subsequently, content analysis will also be performed for each code, to support results from thematic analyses by identifying essential aspects of the content and highlighting the recurrence of themes, to present results clearly and effectively. A final list of themes and subthemes will be determined through patterns as soon as further data that will emerge from the study add little to the emerging theory. Theoretical saturation is reached once no new themes emerge. Results will be reported according to the consolidated criteria for reporting qualitative research developed by Tong *et al*.[@R53]

Ethics and dissemination {#s3}
========================

This study will be conducted in compliance with the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research, the Australian Code for the Responsible Conduct of Research and the Declaration of Helsinki.

Confidentiality {#s3-1}
---------------

Confidentiality and privacy are maintained at every stage of the study. Individual participants will not be identifiable to any other members of their group or anyone else in the wider community. Participants are approached, recruited and contacted in a confidential, one-to-one manner and no public dissemination of participants' details will occur. Contact details for the researchers and relevant ethics committee(s) are provided to address any questions or concerns participants may have. Audio recordings and individual transcripts are being stored on a password protected and secured The University of Melbourne server, which is backed up daily. Study-related records will be retained in a secure storage facility for at least 7 years after the completion of the research as required by the Australian National Health and Medical Research Council.

Dissemination {#s3-2}
-------------

Only deidentified results will be published. The results will be actively disseminated through peer-reviewed scholarly and scientific journals, national and international conference presentations, social media, broadcast media, print media, internet and various community/stakeholder engagement activities. The consumer/patient will also provide comment on the findings and contribute to the dissemination plan via consumer websites such as Breast Cancer Network Australia.

Strengths and limitations of this study {#s4}
=======================================

This will be the first personalised tool considering baseline demographic and lifestyle factors, serum ovarian markers and cancer treatment factors all together in predicting the impact of breast cancer treatments on fertility. Strengths of this study include codesign the tool with patients' and healthcare professionals' needs and preferences in mind. This tool could potentially be implemented globally with adaptation to newer breast cancer treatment. Additionally, the tool could be adapted for other cancer treatments.

Limitations include the use of non-probability sampling to recruit patients with breast cancer, which may increase selection bias.[@R54] Recruitment is limited to patients with breast cancer where fertility was discussed prior to cancer treatment and our findings may not be applicable to circumstances where fertility was not discussed. Also, our findings cannot be generalised to patients with breast cancer from more diverse cultural and linguistic backgrounds and those with advanced breast cancer.
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